What's hot

View all perspectives
What's Hot

Precision Immunotherapy in Axial SpA

Dr. Marina Magrey at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →

PsA: Impact of Sex

Dr. Arthur Kavanaugh discusses abstracts 1709 and 1471, along with a related seminar, presented at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →

Cycling vs Switching after TNFi Failure in axSpA

Dr. Lihi Eder discusses abstract 0603, presented at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →

A Fibroblast Renaissance

Dr. Andrea Fava at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →
men and women

ICYMI: Sex related differences in PsA

Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).

Read more →

Palliative Care in Rheumatology

Dr. Jiha Lee talks with Dr. Shannon Herndon about abstracts 0204 and 1064, presented at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →

Efficacy and Safety of Nipocalimab for Sjogren's Syndrome

Dr. Mike Putman reports on abstract 2527, Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS), presented at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →
PMR,flag

ICYMI: Say Goodbye to Methotrexate in PMR?

For decades, glucocorticoids (GCs) have formed the backbone of polymyalgia rheumatica (PMR) management.

Read more →

Predicting Flares in Rheumatoid Arthritis

Dr. Jonathan Kay interviews Dr. John Isaacs about abstract 1349, presented at the 2024 ACR Convergence meeting in Washington, DC.

Watch video →
statin

ICYMI: ORAL Surveillance - Is Statin Use the Problem/Solution?

The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. Subsequent post-hoc analyses, follow-up studies, and claims data analyses have been used to further interpret the data, though a clear answer on safety is not certain. A study presented on Sunday reported on a new post-hoc analysis that provides new insights.

Read more →
      TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22

      Richard Conway RichardPAConway

      1 year 1 month ago

      TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/pKa4U5L2fW https://t.co/MjzE14SeGi

      Happening now:
      16S18 Into the Weeds: Cannabis in Rheum
      @EleniTiniakou @BharatKumarMD

      Do you discuss marijuana with you

      Eric Dein ericdeinmd

      1 year 1 month ago
      Happening now: 16S18 Into the Weeds: Cannabis in Rheum @EleniTiniakou @BharatKumarMD Do you discuss marijuana with your patients? @RheumNow #ACR24
      Ashgar et al. Metformin reduces risk of TKR in T2DM with OA in meta-analysis. RR 0.59 @RheumNow #ACR24 Abstr#0029 https:

      Richard Conway RichardPAConway

      1 year 1 month ago
      Ashgar et al. Metformin reduces risk of TKR in T2DM with OA in meta-analysis. RR 0.59 @RheumNow #ACR24 Abstr#0029 https://t.co/OhqTJZQwKX https://t.co/RTQUjE6lLy
      Abstr#0647
      Toronto Lupus Clinic finds pericarditis in 20% of #SLE inception cohort, often with skin, heme, MSK, & re

      Akhil Sood MD AkhilSoodMD

      1 year 1 month ago
      Abstr#0647 Toronto Lupus Clinic finds pericarditis in 20% of #SLE inception cohort, often with skin, heme, MSK, & renal involvement. Linked to younger age, White race, +SSB, & lower ACR/EULAR scores - Tx: GC, HCQ, AZA @RheumNow #ACR24
      Abstract #0614
      What is the impact of Lupus on my quality of life?
      Consider using Lupus Impact Tracker (https://t.co/fJQe

      Akhil Sood MD AkhilSoodMD

      1 year 1 month ago
      Abstract #0614 What is the impact of Lupus on my quality of life? Consider using Lupus Impact Tracker (https://t.co/fJQe2uHicM) - high dose GC, comorbidities, and not actively working associated with worse impact on QoL - HCQ shows benefit @RheumNow #ACR24
      #0477 🌍 Global prevalence of RA-ILD

      ➡️21.38% (95% CI 0.15 - 0.29),33 studies, n=14,281

      🔬 Higher RA-ILD risk

      Caoilfhionn Connolly CaoilfhionnMD

      1 year 1 month ago
      #0477 🌍 Global prevalence of RA-ILD ➡️21.38% (95% CI 0.15 - 0.29),33 studies, n=14,281 🔬 Higher RA-ILD risk in smokers, low-income regions, DMARD use. ⛔️Wide CI = heterogeneity main limitation 💡 Screening & lifestyle changes key for high-risk groups. #ACR24 @RheumNow
      Harnessing power of AI in Rheumatology. Strengths and weaknesses of AI will need to be assessed. Amanda Nelson shares th

      Antoni Chan MD (Prof) synovialjoints

      1 year 1 month ago
      Harnessing power of AI in Rheumatology. Strengths and weaknesses of AI will need to be assessed. Amanda Nelson shares the limitation of AI @RheumNow #ACR24 https://t.co/G8FNVco7Qp
      A study in difficult-to-treat (D2T) ankylosing spondylitis (AS) reveals distinct characteristics in patients, including

      Antoni Chan MD (Prof) synovialjoints

      1 year 1 month ago

      A study in difficult-to-treat (D2T) ankylosing spondylitis (AS) reveals distinct characteristics in patients, including: - Higher BMI - Increased comorbidities - Presence of EAMs - HLA-B27 positivity is linked to higher odds of being D2T, highlighting potential genetic… https://t.co/XcShdxSwhm

      Data from the EISER study show that IBD was significantly more prevalent in pts with r-axSpA than nr-axSpA.

      Makes sens

      sheila RHEUMarampa

      1 year 1 month ago
      Data from the EISER study show that IBD was significantly more prevalent in pts with r-axSpA than nr-axSpA. Makes sense in a way since longer dse duration may play a role. 🔶️THM - screen SpA pts for IBD; ask for GI symptoms @RheumNow #ACR24 abs554 https://t.co/Q6jeDUFa8Z
      High PBO effect in PsA studies
      Abst#0772 from U. of Vienna analyzed PBO arms of PsA trials for bDMARDs and tsDMARDs on A

      Adela Castro AdelaCastro222

      1 year 1 month ago
      High PBO effect in PsA studies Abst#0772 from U. of Vienna analyzed PBO arms of PsA trials for bDMARDs and tsDMARDs on ACR response rates at week 12: 💡PBO rates significantly increased over time. 💡Recruitment patterns increasing in geographic areas with less affluent health… https://t.co/wAJnwjYkVe
      Lots of ‘CARTS’, not enough ‘work horses’!

      There are now ~40 CAR-T protocols in #lupus incl many presentations

      Janet Pope Janetbirdope

      1 year 1 month ago
      Lots of ‘CARTS’, not enough ‘work horses’! There are now ~40 CAR-T protocols in #lupus incl many presentations at #ACR24 -most are uncontrolled -selection of pts is key. We need a pathway forward for reg approval & guidelines for studies! @RheumNow @ACRheum 18abst #OOO4 https://t.co/Mckwvn3Ffn
      #0582🔬Challenges in Achieving PsA Disease Control

      ➡️n=2,093; 18% and 8% achieved minimal, very low disease acti

      Caoilfhionn Connolly CaoilfhionnMD

      1 year 1 month ago
      #0582🔬Challenges in Achieving PsA Disease Control ➡️n=2,093; 18% and 8% achieved minimal, very low disease activity respectively 🔑Higher QoL & monotherapy⬆️success; female sex, fatigue, spine pain⬇️outcomes. 🩺Unmet needs remain in PsA; tailored Rx needed #ACR24 @RheumNow
      Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis

      Surprisingly similar rates of remission at week 2

      Mike Putman EBRheum

      1 year 1 month ago
      Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction? #ACR24 @RheumNow Abstr#0670 https://t.co/rO0ufturHW
      Which lupus nephritis patients are at higher risk for CKD? #Abstract0624 shows coexisting tubulointerstitial inflammatio

      Akhil Sood MD AkhilSoodMD

      1 year 1 month ago
      Which lupus nephritis patients are at higher risk for CKD? #Abstract0624 shows coexisting tubulointerstitial inflammation/damage (TII/TID) on renal biopsy is linked to CKD progression (HR 2.667, 95% CI: 1.333-5.335) Risk high among Class III, IV, V and eGFR > 30 @RheumNow #ACR24
      #0501
      💥 JAKi & TNFi show faster short-term RA improvement (3months) compared to IL-6i & ABA

      ➡️n=9590(304

      Caoilfhionn Connolly CaoilfhionnMD

      1 year 1 month ago
      #0501 💥 JAKi & TNFi show faster short-term RA improvement (3months) compared to IL-6i & ABA ➡️n=9590(3049 JAKi, 4606 TNFi, 1284 IL-6, 651 ABA), 14 registers 🕒 JAKi, TNFi improved CDAI, pain, function in 1st two months then stabilised 💡Long-term data needed #ACR24 @RheumNow https://t.co/4yzeAAkGjq

      Podcasts

      • ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights
      • ACR24 JAK TYK Topic Panel
      • RheumNow Day 1 Recap ACR Convergence 2024 Highlights

      Catch up on Conference Podcasts

      ×